Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 87
Filter
1.
Biol Invasions ; 19(8): 2225-2235, 2017.
Article in English | MEDLINE | ID: mdl-28798542

ABSTRACT

The bryozoan Schizoporella japonica Ortmann (1890) was first recorded in European waters in 2010 and has since been reported from further locations in Great Britain (GB) and Norway. This paper provides a new earliest European record for the species from 2009, a first record from Ireland and presence and absence records from a total of 231 marinas and harbours across GB, Ireland, the Isle of Man, France and Portugal. This species is typically associated with human activity, including commercial and recreational vessels, aquaculture equipment, and both wave and tidal energy devices. It has also been observed in the natural environment, fouling rocks and boulders. The species has an extensive but widely discontinuous distribution in GB and Ireland. Although found frequently in marinas and harbours in Scotland, it inhabits only a few sites in England, Wales and Ireland, interspersed with wide gaps that are well documented as genuine absences. This appears to be a rare example of a southward-spreading invasion in GB and Ireland. The species has been reported from the Isle of Man and Norway but has not been found in France or Portugal. In the future we expect S. japonica to spread into suitable sections of the English, Welsh and Irish coasts, and further within Europe. The species' capability for long-distance saltatory spread and potential for negative impact on native ecosystems and economic activity suggests that S. japonica should now be considered invasive in GB and Ireland. As such, it is recommended that biosecurity procedures alongside effective surveillance and monitoring should be prioritised for regions outside the species' current distribution.

2.
Mar Pollut Bull ; 62(10): 2137-44, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21820680

ABSTRACT

Boat harbours are an increasingly common form of artificial habitat. This paper presents a comparative study of contaminants and foulers of a habitat-forming native kelp (Saccharina latissima) in four marinas and four reference locations along the south-west coast of the UK. Fouling of algal laminae was light (<2% cover) in reference locations, while epibiota cover ranged from 25% to 80% of laminae in marinas. Metals associated with antifouling paints were up to six times more concentrated in algal tissues from marinas than from the reference locations. Marinas also carried the greatest cover and diversity of non-indigenous epibiota on the kelp laminae. This indicates not only a potential stress to kelps in these environments, but also the possibility that detached laminae will act as vectors for the dispersal of non-indigenous species. The development of boat harbours creates habitats that are high risk source localities for pollution-tolerant fouling organisms.


Subject(s)
Ecosystem , Kelp/metabolism , Ships , Water Pollutants, Chemical/metabolism , Biodiversity , Biota , Disinfectants/metabolism , Environmental Monitoring , Metals/metabolism , Water Pollutants, Chemical/analysis
3.
Physiol Biochem Zool ; 83(5): 858-68, 2010.
Article in English | MEDLINE | ID: mdl-20695812

ABSTRACT

Questions about the adaptive importance of metabolic rate can be approached only when measurements of differences between individuals are repeatable. We made daily measurements of CO(2) production, body mass, and food uptake over the adult life span of unmated Vanessa cardui kept under constant environmental conditions in both fed and unfed treatments. Mass and CO(2) production generally declined with age in both treatments, though with much day-to-day variability in the fed treatment. For the full samples, metabolic rate was repeatable for the unfed treatment (repeatability r = 0.60) but not for the fed treatment (r = 0.03). Differences between fed and unfed individuals of the same age range were repeatable for the unfed treatment (r = 0.39) but not for the fed treatment (r = -0.20). Removing age effects on CO(2) production yielded still higher repeatability in the unfed treatment (r = 0.83), though not in fed butterflies of the same age range (r = -0.02). However, repeatability of CO(2) production of fed butterflies increased sharply with age, rising to 0.82 for butterflies age 8-10 d. Although food uptake mass was repeatable (r = 0.52), feeding history explained little variation in CO(2) production. We conclude that for V. cardui and possibly for other insects of similar feeding habit, variation in metabolic rate between individuals is best represented by measurements of unfed individuals of the same age or of older fed individuals.


Subject(s)
Aging/physiology , Butterflies/physiology , Eating/physiology , Energy Metabolism/physiology , Analysis of Variance , Animals , Body Weight , Carbon Dioxide/metabolism
4.
Vet Rec ; 160(10): 321-6, 2007 Mar 10.
Article in English | MEDLINE | ID: mdl-17351172

ABSTRACT

The efficacy and toxicity of orthovoltage radiation therapy and concurrent low doses of doxorubicin for the treatment of incompletely excised soft-tissue sarcomas in 39 dogs was investigated retrospectively. The 39 dogs had 40 soft-tissue sarcomas and received 51 Gy orthovoltage radiation in 17 daily 3 Gy fractions; they also received 10 mg/m(2) doxorubicin once a week administered intravenously one hour before the dose of radiation. The median follow-up time was 910 days. The tumours recurred locally in seven of the dogs, in five of them within the radiation field; the median time to their recurrence was 213 days (range 63 to 555 days). Six of the dogs developed a distant metastasis after a median time of 276 days (range eight to 826 days). The one-year and two- to four-year tumour control rates were 84 per cent and 81 per cent, respectively, and the one-, two- and three- to four-year survival rates were 85 per cent, 79 per cent and 72 per cent, respectively. Tumours with a mitotic rate of more than 9 per 10 high-power fields were significantly more likely to recur, and the dogs with such tumours survived for significantly shorter periods.


Subject(s)
Antineoplastic Agents/administration & dosage , Dog Diseases/drug therapy , Dog Diseases/radiotherapy , Doxorubicin/administration & dosage , Neoplasm Recurrence, Local/veterinary , Sarcoma/veterinary , Soft Tissue Neoplasms/veterinary , Animals , Combined Modality Therapy/veterinary , Disease-Free Survival , Dog Diseases/mortality , Dog Diseases/pathology , Dog Diseases/surgery , Dogs , Female , Infusions, Intravenous/veterinary , Male , Massachusetts , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/radiotherapy , Radiation Dosage , Records/veterinary , Retrospective Studies , Sarcoma/drug therapy , Sarcoma/radiotherapy , Soft Tissue Neoplasms/drug therapy , Soft Tissue Neoplasms/radiotherapy , Survival Analysis , Treatment Outcome
5.
Eur J Clin Microbiol Infect Dis ; 25(10): 633-41, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17024505

ABSTRACT

The study presented here compared the efficacy and safety of ertapenem and cefepime as initial treatment for adults with pneumonia acquired in skilled-care facilities or in hospital environments outside the intensive care unit (ICU). Non-ventilated patients developing pneumonia in hospital environments outside the ICU, in nursing homes, or in other skilled-care facilities were enrolled in this double-blind non-inferiority study, stratified by APACHE II score (15) and randomized (1:1) to receive cefepime (2 g every 12 h with optional metronidazole 500 mg every 12 h) or ertapenem (1 g daily). After 3 days of parenteral therapy, participants demonstrating clinical improvement could be switched to oral ciprofloxacin or another appropriate oral agent. Probable pathogens were identified in 162 (53.5%) of the 303 randomized participants. The most common pathogens were Enterobacteriaceae, Streptococcus pneumoniae, and Staphylococcus aureus, isolated from 59 (19.5%), 39 (12.9%), and 35 (11.6%) participants, respectively. At the test-of-cure assessment 7-14 days after completion of all study therapy, pneumonia had resolved or substantially improved in 89 (87.3%) of 102 clinically evaluable ertapenem recipients and 80 (86%) of 93 clinically evaluable cefepime recipients (95% confidence interval for the difference, -9.4 to 11.8%), fulfilling pre-specified criteria for statistical non-inferiority. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. In this study population, ertapenem was as well-tolerated and efficacious as cefepime for the initial treatment of pneumonia acquired in skilled-care facilities or in hospital environments outside the ICU.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Cephalosporins/administration & dosage , Cross Infection/drug therapy , Pneumonia, Bacterial/drug therapy , beta-Lactams/administration & dosage , Aged , Anti-Bacterial Agents/adverse effects , Cefepime , Cephalosporins/adverse effects , Cross Infection/microbiology , Double-Blind Method , Drug Administration Schedule , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/microbiology , Ertapenem , Female , Humans , Intensive Care Units , Male , Middle Aged , Pneumonia, Bacterial/microbiology , Prospective Studies , Skilled Nursing Facilities , beta-Lactams/adverse effects
6.
J Evol Biol ; 17(3): 506-18, 2004 May.
Article in English | MEDLINE | ID: mdl-15149394

ABSTRACT

The importance of sexual compatibility between mates has only recently been realized in zoological research into sexual selection, yet its study has been central to botanical research for many decades. The reproductive characteristics of remote mating, an absence of precopulatory mate screening, internal fertilization and embryonic brooding are shared between passively pollinated plants and a phylogenetically diverse group of sessile aquatic invertebrates. Here, we further characterize the sexual compatibility system of one such invertebrate, the colonial ascidian Diplosoma listerianum. All 66 reciprocal pairings of 12 genetic individuals were carried out. Fecundities of crosses varied widely and suggested a continuous scale of sexual compatibility. Of the 11 animals from the same population c. 40% of crosses were completely incompatible with a further c. 20% having obvious partial compatibility (reduced fecundity). We are unaware of other studies documenting such high levels of sexual incompatibility in unrelated individuals. RAPD fingerprinting was used to estimate relatedness among the 12 individuals after a known pedigree was successfully reconstructed to validate the technique. In contrast to previous results, no correlation between genetic similarity and sexual compatibility was detected. The blocking of many genotypes of sperm is expected to severely modify realized paternity away from 'fair raffle' expectations and probably reduce levels of intra-brood genetic diversity in this obligatorily promiscuous mating system. One adaptive benefit may be to reduce the bombardment of the female reproductive system by outcrossed sperm with conflicting evolutionary interests, so as to maintain female control of somatic : gametic investment.


Subject(s)
Genetic Variation , Sexual Behavior, Animal/physiology , Urochordata/genetics , Urochordata/physiology , Animals , Crosses, Genetic , Disorders of Sex Development , Female , Fertility/physiology , Fertilization/physiology , Male , Oocytes/physiology , Random Amplified Polymorphic DNA Technique , Spermatozoa/physiology
7.
Vet Comp Oncol ; 1(4): 171-9, 2003 Dec.
Article in English | MEDLINE | ID: mdl-19379178

ABSTRACT

A retrospective analysis was done to assess the toxicity and efficacy associated with an alternating chemotherapy protocol of ifosfamide (375 mg m(-2)) and doxorubicin (30 mg m(-2)) for adjuvant treatment of 39 dogs with sarcomas. Twelve dogs had various soft-tissue sarcomas and 27 dogs had hemangiosarcoma (HSA). Complete blood counts were evaluated 7 days after the first dose of ifosfamide and doxorubicin. One dog had grade 4 neutropenia (<500 microL(-1)) after treatment with ifosfamide and one dog had grade 3 neutropenia (500-1000 microL(-1)) after treatment with doxorubicin. One dog treated with doxorubicin was hospitalized for 24 h due to vomiting. The median survival time (ST) for the 27 dogs with HSA treated by surgery and with doxorubicin/ifosfamide was 149 days (mean 366 days). Although the protocol of alternating ifosfamide and doxorubicin was well tolerated, it failed to result in a statistically significant improvement in the ST when compared to a historical population of dogs with stage 2 splenic HSA treated by surgery alone.

8.
Vet Comp Oncol ; 1(2): 86-93, 2003 Jun.
Article in English | MEDLINE | ID: mdl-19379320

ABSTRACT

A colloidal dispersion formulation of 9-aminocamptothecin (9-AC) was administered intravenously to 10 dogs with previously untreated, spontaneously occurring, multicentric lymphoma. The dogs received a 72-h infusion of 9-AC at a rate of 46.5-51.25 microg m(-2) h(-1) (total dose range 3.35-3.69 mg m(-2)). This dose range was associated with myelosuppression, consisting principally of neutropenia with a nadir at 7 days following the start of infusion. Neutropenia and thrombocytopenia were the most common toxicoses and are most likely to be dose-limiting toxicities; low-grade gastrointestinal signs were rarely seen. Concentrations of 9-AC lactone, as well as clinical toxicities, compare favourably with those found in humans. Tumour responses were seen in all treated dogs. Response to other chemotherapy, following cessation of 9-AC treatment, was not obviously compromised even in dogs clinically resistant to 9-AC. 9-AC is a novel treatment drug for canine lymphoma, which appears to show great promise.

10.
Clin Infect Dis ; 33(11): 1816-23, 2001 Dec 01.
Article in English | MEDLINE | ID: mdl-11668430

ABSTRACT

Clinicians caring for patients with vancomycin-resistant Enterococcus faecium (VREF) infections face severe constraints in the selection of treatment. Quinupristin/dalfopristin (Synercid) is active in vitro against VREF, with a MIC(90) of 1.0 microg/mL. We investigated the clinical efficacy and safety of this agent in a multicenter, prospective, noncomparative, emergency-use study of 396 patients. Patients were included if they had signs and symptoms of active infection, including bacteremia of unknown origin, intra-abdominal infection, and skin and skin-structure infection, with no alternative antibiotic therapy available. The mean duration of treatment was 20 days (range, 4-40 days). The clinical response rate was 68.8% in the evaluable subset, and the overall response rate was 65.6%. The most common adverse events related to quinupristin/dalfopristin were arthralgias and myalgias. Related laboratory abnormalities were rare. In this severely ill patient population, quinupristin/dalfopristin was efficacious and demonstrated an acceptable safety profile in the treatment of VREF infection.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Enterococcus faecium , Gram-Positive Bacterial Infections/drug therapy , Vancomycin Resistance , Virginiamycin/therapeutic use , Anti-Bacterial Agents/adverse effects , Drug Resistance, Bacterial , Gram-Positive Bacterial Infections/complications , Gram-Positive Bacterial Infections/diagnosis , Humans , Superinfection/complications , Treatment Outcome , Virginiamycin/adverse effects
11.
J Vet Intern Med ; 15(4): 348-54, 2001.
Article in English | MEDLINE | ID: mdl-11467592

ABSTRACT

Eighty-two dogs with lymphoma received a single 15-week course of chemotherapy, after which treatment was ceased until relapse. Fifty-six dogs (68%) achieved complete remission for a median 1st remission duration of 20 weeks. Forty-eight dogs relapsed, of which 30 repeated the induction cycle. In 22 of these dogs, 1st remission had been short, and they received maintenance chemotherapy; the other 8 dogs received 2 or 3 cycles of induction chemotherapy. Second remission rate for these 30 dogs was 87% (26 dogs). Overall disease control for the 38 dogs that remained on protocol was 44 weeks, which was not markedly shorter than for dogs treated with a previously reported protocol in which maintenance chemotherapy was instituted in all dogs after an identical 1st induction (VELCAP-L). Dogs that were febrile and dogs that were dyspneic were less likely to achieve a complete remission to induction chemotherapy. Of dogs that achieved a complete remission, those that were thrombocytopenic at entry had a shorter 1st remission, and dogs that were anorexic at entry had shorter overall disease control. There was a correlation between 1st remission duration and length of any subsequent remission obtained. The incidence of toxicity was high, particularly after the combination of doxorubicin and vincristine. Dose reductions because of toxicity did not markedly reduce remission duration. We conclude that discontinuous chemotherapy may reduce patient visits in a small number of patients because of long-term disease control. Delaying maintenance chemotherapy until after 2nd remission is achieved does not markedly affect overall disease control.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Lymphoma/veterinary , Animals , Asparaginase/administration & dosage , Breeding , Cyclophosphamide/administration & dosage , Disease-Free Survival , Dogs , Doxorubicin/administration & dosage , Drug Administration Schedule , Female , Lymphoma/drug therapy , Male , Prednisone/administration & dosage , Records/veterinary , Retrospective Studies , Treatment Outcome , Vincristine/administration & dosage
12.
J Vet Intern Med ; 14(3): 271-6, 2000.
Article in English | MEDLINE | ID: mdl-10830540

ABSTRACT

lfosfamide (3-[2-chloroethyl]-2[(2 chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) is an alkylating agent with a broad spectrum of antitumor activity. The efficacy and toxicity of ifosfamide were evaluated in 72 dogs with spontaneously occurring tumors. Forty dogs (56%) had lymphoma, 31 (43%) had sarcomas, and 1 had a metastatic carcinoma. Five dogs received ifosfamide at dosages <350 mg/m2 IV. Neither toxicity nor response were observed, and the remaining dogs received ifosfamide at 350 mg/m2 (n = 18) and 375 mg/m2 body surface area IV (n = 49). Saline diuresis and the thiol compound mesna were used to prevent urothelial toxicity. Fifty-two dogs had measurable tumors and could be evaluated for response. Complete responses were seen in 1 dog with metastatic leiomyosarcoma of the urinary bladder and in 1 dog with metastatic cutaneous hemangiosarcoma. One dog with lymphoma had a partial response for 112 days. Six dogs with splenic hemangiosarcoma received ifosfamide postsplenectomy and their median survival time was 147 days. The acute dose limiting toxicity was neutropenia 7 days after administration of ifosfamide. The median and mean neutrophil counts 7 days after ifosfamide at 350 mg/m2 were 2,035 cells/microL and 4,773 cells/microL, respectively (n = 12). The median and mean neutrophil counts 7 days after ifosfamide at 375 mg/m2 were 2,500 cells/microL and 3,594 cells/microL, respectively (n = 37). No dog developed clinical or microscopic evidence of hemorrhagic cystitis. Ifosfamide appears safe to use in tumor-bearing dogs, and the evaluation of combination chemotherapy protocols that include ifosfamide should be considered.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Dog Diseases/drug therapy , Ifosfamide/therapeutic use , Lymphoma/veterinary , Sarcoma/veterinary , Animals , Dog Diseases/mortality , Dogs , Female , Lymphoma/drug therapy , Lymphoma/mortality , Male , Massachusetts/epidemiology , Records/veterinary , Retrospective Studies , Sarcoma/drug therapy , Sarcoma/mortality , Survival Analysis , Treatment Outcome
13.
J Feline Med Surg ; 2(1): 57-60, 2000 Mar.
Article in English | MEDLINE | ID: mdl-11716592

ABSTRACT

Orthovoltage radiation was used to treat odontogenic tumours in three cats following incomplete surgical resection. Cats received a total radiation dose of 48-52 Gy over a period of 26-29 days. Acute toxicities were mild, consisting of hair loss within the radiation field in all cats, and mild mucositis in one cat. All cats had long-term (>35 months) control of their tumour, and two cats are still alive without recurrence of tumour 60 and 39 months, respectively, after completing treatment. Radiation therapy should be considered to be an adjuvant to incomplete surgery in cats with odontogenic neoplasms or epulides.


Subject(s)
Cat Diseases/radiotherapy , Gingival Diseases/veterinary , Maxillary Neoplasms/veterinary , Odontogenic Tumors/veterinary , Animals , Cats , Chemotherapy, Adjuvant/veterinary , Female , Gingival Diseases/radiotherapy , Male , Maxillary Neoplasms/radiotherapy , Neoplasm Recurrence, Local/radiotherapy , Neoplasm Recurrence, Local/veterinary , Odontogenic Tumors/radiotherapy , Palliative Care , Radiotherapy Dosage
14.
J Vet Intern Med ; 13(5): 395-8, 1999.
Article in English | MEDLINE | ID: mdl-10499719

ABSTRACT

Forty-three dogs with lymphoma that had relapsed or had failed to achieve complete remission to previous chemotherapy were treated with lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea [CCNU]) at a dosage of 90-100 mg/m2 body surface area p.o. every 3 weeks. Durable complete or partial responses occurred in 11 dogs for a median of 86 days. The acutely dose-limiting toxicosis was neutropenia 7 days after administration, resulting in a recommended dosage of 90 mg/m2. Cumulative thrombocytopenia occurred in dogs receiving continued CCNU treatment, and a dose interval of 3 weeks may be too short for continued administration of this drug. Toxicoses evident as fever or central nervous system signs or renal damage were uncommon or rare. CCNU is effective in the treatment of relapsed lymphoma.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Dog Diseases/drug therapy , Lomustine/therapeutic use , Lymphoma/veterinary , Animals , Antineoplastic Agents, Alkylating/adverse effects , Dogs , Drug Resistance, Neoplasm , Female , Lomustine/adverse effects , Lymphoma/drug therapy , Male , Neutropenia/chemically induced , Recurrence , Thrombocytopenia/chemically induced , Treatment Outcome
15.
Ophthalmology ; 106(4): 683-7, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10201587

ABSTRACT

OBJECTIVE: To compare the distribution of cataract types between psychiatric patients diagnosed with schizophrenia and the general population not exposed to psychotropic medication, and to compare cataract prevalence between users and nonusers of various psychotropic medications in the general community. DESIGN: Case-control. PARTICIPANTS: A total of 151 (93%) eligible patients from a community mental health service and 3271 (83%) eligible residents from the Melbourne Visual Impairment Project (VIP) were examined. MAIN OUTCOME MEASURES: All patients 40 years of age and older from a community mental health service and residents of nine randomly selected areas of Melbourne were eligible. Best-corrected distance visual acuity was determined using a 4-m logarithm of the minimum angle of resolution (LogMAR) chart. The presence of cataract was determined by photographs or slit-lamp examination using direct and indirect retroillumination. Anterior, cortical, nuclear, and posterior subcapsular cataracts were measured. Participants from the Melbourne VIP were classified as to whether they had taken benzodiazepams, phenothiazines, thioxanthenes, butyrophenols, tricyclic antidepressants, or monoamine oxidase inhibitors for at least 12 months during their lifetime. RESULTS: The distribution of cataract type varied between persons with and without schizophrenia. Anterior subcapsular (ASC) cataract was significantly more prevalent (26%) in participants with schizophrenia from the community mental health service than Melbourne VIP participants (0.2%) not exposed to psychotropic medication (chi-square, 1 degree of freedom = 605.5, P = 0.001). This remained significant after controlling for age (odds ratios = 250, 95% confidence interval = 83.3, 1000). The distribution of the age-related cataract was similar across all groups of psychotropic medication users with the exception of the phenothiazine users. They had less of all types of the age-related cataracts, despite being slightly older than the control group (mean age, 60.0 vs. 58.4, t test = 0.85, P = 0.40). However, only cortical cataract in the phenothiazine group was statistically lower (chi-square, 1 degree of freedom = 3.96, P = 0.047). CONCLUSION: This study has identified the need to investigate whether other newer agents, especially high-potency medications, cause ASC opacities if a certain threshold of exposure to psychotropic medications must be attained to develop cataract, or if schizophrenia itself is associated with cataract formation.


Subject(s)
Antidepressive Agents/therapeutic use , Cataract/epidemiology , Heterocyclic Compounds/therapeutic use , Monoamine Oxidase Inhibitors/therapeutic use , Psychotropic Drugs/therapeutic use , Schizophrenia/drug therapy , Adult , Aged , Aged, 80 and over , Antidepressive Agents/adverse effects , Australia/epidemiology , Case-Control Studies , Cataract/chemically induced , Cataract/pathology , Community Mental Health Services/statistics & numerical data , Female , Heterocyclic Compounds/adverse effects , Humans , Lens, Crystalline/drug effects , Lens, Crystalline/pathology , Male , Middle Aged , Monoamine Oxidase Inhibitors/adverse effects , Prevalence , Psychotropic Drugs/adverse effects , Risk Factors
16.
J Vet Intern Med ; 12(6): 465-70, 1998.
Article in English | MEDLINE | ID: mdl-9857340

ABSTRACT

Ninety-eight dogs with lymphoma treated with a 5-drug combination chemotherapy regimen (vincristine, L-asparaginase, cyclophosphamide, doxorubicin, prednisone [VELCAP-L]) were evaluated for pretreatment characteristics predictive for response and remission duration. The complete remission rate was 69%, with a median remission duration of 55 weeks. Dogs with advanced stage of disease, constitutional signs, dogs that were older, and dogs that were dyspneic were less likely to achieve remission. Once in remission, small dogs and dogs without pretreatment thrombocytopenia were likely to have longer remission duration. Toxicoses were frequent, but rarely fatal, and no predictitive factors were found for a dog developing toxicoses. VELCAP-L is an effective treatment for dogs in stage I-III lymphoma, particularly in young, small animals.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Lymphoma/veterinary , Age Factors , Animals , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Asparaginase/administration & dosage , Asparaginase/adverse effects , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Dogs , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Female , Lymphoma/drug therapy , Male , Neoplasm Staging/veterinary , Prednisone/administration & dosage , Prednisone/adverse effects , Prognosis , Remission Induction , Sex Factors , Treatment Outcome , Vincristine/administration & dosage , Vincristine/adverse effects
17.
Aust N Z J Public Health ; 22(2): 220-2, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9744180

ABSTRACT

BACKGROUND: People with diabetes do not regularly utilise eye services for the early prevention of vision loss due to diabetic eye disease. A community-based screening program has been initiated in Victoria to address this issue. To encourage people to take preventive eye health care measures, the most effective health promotion strategies were identified. METHODS: Thirty-three health professionals were invited to attend focus groups. A sample of 35 people with diabetes was approached by their GPs or diabetes educators because of their motivation to participate in diabetes activities. Each group consisted of 10 members. Discussion points included the type of education messages available to people with diabetes; use of eye services among the participants with diabetes; and strategies required promoting the screening service. RESULTS: Five focus groups were conducted. The discussions highlighted that a great deal could be achieved by using local community networks to promote the benefits of early detection of diabetic retinopathy and local screening program. The group members recommended that particular attention be directed to general practitioners and their distribution of materials to patients. Key issues for planning and implementing the program were highlighted. The groups urged development of strategies to encourage people with diabetes in rural Victoria to participate in a program for the early detection of diabetic retinopathy.


Subject(s)
Diabetic Retinopathy/diagnosis , Focus Groups , Health Promotion/methods , Humans , Mass Screening , Research Design , Victoria
18.
J Am Anim Hosp Assoc ; 34(5): 417-21, 1998.
Article in English | MEDLINE | ID: mdl-9728473

ABSTRACT

A retrospective analysis was performed on the case records of 32 dogs with Stage I or II splenic hemangiosarcoma that were treated by splenectomy alone and that survived the seven-day postoperative period. Median survival time for these 32 cases was 86 days (mean, 116 days; range, 14 to 470 days), and the one-year survival rate was estimated to be 6.25%. Survival was not influenced by signalment, presenting signs, stage of disease, or clinicopathological findings. The data provides a basis from which to evaluate adjuvant chemotherapy for splenic hemangiosarcoma that is confined to the spleen macroscopically.


Subject(s)
Dog Diseases/mortality , Hemangiosarcoma/veterinary , Splenectomy/veterinary , Splenic Neoplasms/veterinary , Animals , Dog Diseases/surgery , Dogs , Female , Follow-Up Studies , Hemangiosarcoma/mortality , Hemangiosarcoma/surgery , Male , Prognosis , Retrospective Studies , Splenic Neoplasms/mortality , Splenic Neoplasms/surgery , Survival Analysis , Survival Rate , Time Factors
20.
Clin Geriatr Med ; 14(2): 267-83, 1998 May.
Article in English | MEDLINE | ID: mdl-9536105

ABSTRACT

Urinary tract infection is common among older adults, although most individuals are asymptomatic. The prevalence of bacteriuria varies significantly with living situation and functional status. Asymptomatic bacteriuria is a benign condition and is not an independent risk factor for mortality in older adults. Treatment of asymptomatic bacteriuria generally is not indicated, but symptomatic urinary tract infection of the lower or upper tract dictates antibiotic therapy.


Subject(s)
Urinary Tract Infections/epidemiology , Age Factors , Aged , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents, Urinary/therapeutic use , Bacteriuria/diagnosis , Bacteriuria/drug therapy , Bacteriuria/epidemiology , Cross Infection/drug therapy , Cross Infection/epidemiology , Female , Humans , Incidence , Male , Prevalence , Urinary Tract Infections/diagnosis , Urinary Tract Infections/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...